Side-by-side · Research reference

P21vsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED8/36 cited

BPhase 3HUMAN-REVIEWED8/39 cited

P21

CNTF-Derived Neuropeptide · Animal Model Evidence

CNTFR/gp130Primary receptorGuo 2022

Animal onlyEvidence level

NeurogenesisPrimary effectJia 2020 Mottolese 2024

SQ · Site unspecified · Frequency unknown

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

P21

Thymosin α-1

Primary target

CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

—

Origin

Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

—

02Dosage Protocols

Parameter

P21

Thymosin α-1

Human dosing

No established protocol

No clinical trial data available.

—

Animal models (mice)

Dose and route not specified in abstractsMottolese 2024 Jia 2020

In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.

—

Evidence basis

Animal models only

CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024 Cox 2026 Jia 2020

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Duration

Not specified

6–12 months for chronic indications

Route

Presumed subcutaneous or intraperitoneal (animal studies)

—

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

Frequency

—

2× weekly (Mon/Thu typical)

Lower / starter dose

—

0.8 mg per injection

Reconstitution

—

Sterile water for injection per vial label

Timing

—

No specific time

Half-life

—

~2 hours plasma; tissue effect days

04Side Effects & Safety

Parameter

P21

Thymosin α-1

Human safety data

None available

No clinical trials in humans.

—

Animal tolerability

Well-tolerated in mouse models; no toxicity reported in available abstracts

—

Theoretical risks

Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects

—

Injection site reaction

—

Erythema, mild discomfort

GI symptoms

—

Rare nausea

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Cancer risk

—

No signal — used as adjuvant in oncology

Pregnancy / OB

—

Avoid

Absolute Contraindications

P21

·Use in humans not validated

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

P21

·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
·Pregnancy or lactation (no safety data)

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

P21

Thymosin α-1

1. Human protocol

Not established. No FDA approval, no clinical trial data.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Animal research context

In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Timing

—

2× weekly, e.g. Monday + Thursday.

4. Storage

—

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Needle

—

27–31G, 4–8 mm insulin syringe.